Is Amwill Health overvalued or undervalued?

As of 16 September 2025, Amwill Health's valuation grade has moved from fair to expensive, indicating a shift in its perceived market value. The company is currently considered overvalued. Key ratios include a PE ratio of 11.54, an EV to EBITDA of 10.36, and a Price to Book Value of 1.79, which suggest that the stock may not offer sufficient growth potential relative to its price.
In comparison to peers, Amwill Health's PE ratio is significantly lower than that of Sun Pharma Industries, which stands at 33.64, and Divi's Laboratories, which is at 70. This highlights that while Amwill Health is categorized as expensive, its valuation metrics are more favorable than those of its higher-valued peers. Notably, the company's recent stock performance has outpaced the Sensex over the past week, returning 6.74% compared to the Sensex's 1.58%, but this does not alter the overall assessment of its current valuation.